Lorcaserin for Preventing Weight Gain Among Smokers
2017年5月9日 更新者:Ryan T. Hurt, M.D., Ph.D.、Mayo Clinic
Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study
This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.
研究概览
详细说明
This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline.
The investigators will obtain preliminary data on the efficacy of lorcaserin (10 mg twice daily) for 12 weeks in 20 adult weight-concerned cigarette smokers with a BMI of 27 to 40 simultaneously receiving 12 weeks of open-label varenicline and a behavioral intervention to assist with stopping smoking.
Secondary aims will be weight, waist circumference, and smoking cessation.
研究类型
介入性
注册 (实际的)
20
阶段
- 阶段2
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic in Rochester
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- ≥18 years and ≤65 years of age;
- smoked ≥10 cigarettes/day for the past 6 months;
- BMI of 27-40 kg/m2;
- resides within the Olmsted County area;
- motivated to stop smoking;
- weight concerned as shown with the Weight Concern Scale;
- able to participate fully in all aspects of the study;
- understood and signed the study informed consent.
Exclusion Criteria:
- current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt (defined by the Columbia-Suicide Severity Rating Scale [C-SSRS] as a "potentially self-injurious act committed with at least some wish to die, as a result of act.");
- current moderate or severe depression as assessed by a score of ≥16 on the Center for Epidemiologic Studies-Depression (CES-D);
- a lifetime history of bipolar disorder or schizophrenia;
- use of anti-psychotic medication within the past 30 days;
- use of weight-loss medications within the past 30 days or current participation in a program specifically designed to help with weight loss;
- weight fluctuations of 20 pounds or more in the past 6 months (self-report);
- use of any treatments for tobacco dependence within the past 30 days;
- use of an investigational drug within the past 30 days;
- recent history (past 3 months) of abuse of or dependence on a substance other than tobacco;
- current use of benzodiazepines, narcotics, anti-epileptics, or other medications known to interact with lorcaserin (see human subjects section);
- current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), dextromethorphan, tricyclic antidepressants (TCAs), bupropion, lithium, tramadol, tryptophan, and St. John's Wort, or any other medication known to involve the serotonergic neurotransmitter system (see human subjects section);
- uncontrolled hypertension (systolic >160 mm Hg and/or diastolic >100 mm Hg) documented on 2 separate occasions;
- clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, respiratory, or metabolic disease;
- current use of medications known to interact with varenicline or lorcaserin;
- another household member or relative participating in the study;
- Known Diabetes;
- a known allergy to varenicline or lorcaserin;
- have taken antibiotics within the past 3 months.
- Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine device, surgical sterilization, and abstinence.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Varenicline + Lorcaserin
Open label all subjects receive both Varenicline and Lorcaserin
|
All subjects receive Varenicline
其他名称:
All subjects receive Lorcaserin
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Post Cessation Weight Change
大体时间:12 weeks
|
change in weight from baseline to week 12
|
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Waist Circumference
大体时间:12 Weeks
|
Change in waist circumference from baseline to week 12
|
12 Weeks
|
|
Smoking Abstinence Rates
大体时间:12 weeks
|
prolonged smoking abstinence at week 12
|
12 weeks
|
|
BMI
大体时间:12 weeks
|
Change in BMI from baseline to week 12
|
12 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 首席研究员:Ryan Hurt, MD, PhD、Mayo Clinic
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年9月1日
初级完成 (实际的)
2015年12月1日
研究完成 (实际的)
2015年12月1日
研究注册日期
首次提交
2015年3月13日
首先提交符合 QC 标准的
2015年3月18日
首次发布 (估计)
2015年3月19日
研究记录更新
最后更新发布 (实际的)
2017年6月6日
上次提交的符合 QC 标准的更新
2017年5月9日
最后验证
2017年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.